Хронический бронхит – новые клинические рекомендации (основные положения)

1. Miravitlles M, Soriano JB, García-Río F, et al. Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities. Thorax. 2009;64(10):863-8. DOI:10.1136/thx.2009.115725
2. Martinez C, Chen Y, Kazerooni E, et al. Non-obstructive chronic bronchitis in the COPDGene cohort. Am J Respir Crit Care Med. 2012;185:A6622. DOI:10.1164/ajrccm-conference.2012.185.1_MeetingAbstracts.A6622
3. Косарев В.В., Бабанов С.А. Социальные аспекты хронического бронхита по данным эпидемиологического исследования. Экология человека. 2005;12:46-9 [Kosarev VV, Babanov SA. Social aspects of chronic bronchitis according to data of epidemiologic study. Ekologiia cheloveka. 2005;12:46-9 [(in Russian)]. 
4. Smith JA, Woodcock A. Chronic cough. N Engl J Med. 2016;375:1544-51. DOI:10.1056/NEJMcp1414215
5. Лещенко И.В., Демко И.В., Зайцев А.А., и др. Хронический бронхит. Под ред. И.В. Лещенко. М.: ГЭОТАР-Медиа, 2021 [Leshchenko IV, Demko IV, Zaytsev AA, et al. Khronicheskii bronkhit. Pod red. IV Leshchenko. Moscow: GEOTAR-Media, 2021 (in Russian)]. 
6. Зайцев А.А., Оковитый С.В., Крюков Е.В. Кашель. Практическое пособие для врачей. М., 2015 [Zaitsev AA, Okovityi SV, Kriukov EV. Kashel. Prakticheskoie posobie dlia vrachei. Moscow, 2015 (in Russian)].
7. Terasaki G, Paauw DS. Evaluation and treatment of chronic cough. Med Clin N Am. 2014;98:91-403. DOI:10.1016/j.mcna.2014.01.002
8. Achilleos A. Evidence-based evaluation and management of chronic cough. Med Clin N Am. 2016;100:1033-45. DOI:10.1016/j.mcna.2016.04.008
9. Dotan Y, So JY, Kim V. Chronic Bronchitis: Where Are We Now? Chronic Obstr Pulm Dis. 2019;6(2):178-92. DOI:10.15326/jcopdf.6.2.2018.0151
10. Lai K, Shen H, Zhou X, et al. Clinical practice guidelines for diagnosis and management of cough: Chinese Thoracic Society (CTS) Asthma Consortium. J Thorac Dis. 2018;10:6314-51. DOI:10.21037/jtd.2018.09.153
11. Irwin RS. Chronic Cough Due to Gastroesophageal Reflux Disease ACCP evidence-based clinical practice guidelines. Chest. 2006;129(Suppl. 1):59S-62S. DOI:10.1378/chest.129.1_suppl.80S
12. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106(2):196-204. DOI:10.7326/0003-4819-106-2-196
13. Woodhead M, Blasi F, Ewig S, et al. New guidelines for the management of adult lover respiratory tract infections. Clin Microbiol Infect. 2011;17(6):1-59. DOI:10.1111/j.1469-0691.2011.03602.x
14. Irwin RS, Baumann MH, Bolser DC, et al. Diagnosis and management of cough executive summary: ACCP evidence-based clinical practice guidelines. Chest. 2006;29(1 Suppl.):1S-23S. DOI:10.1378/chest.129.1_suppl.1S
15. Morice AH, Millqvist E, Bieksiene K, et al. ERS guidelines on the diagnosis and treatment of chronic cough in adults and children. Eur Respir J. 2020;55:1901136 DOI:10.1183/13993003.01136-2019
16. Chandler MA, Rennard SI. Smoking cessation. Chest. 2010;137:428-35. DOI:10.1378/chest.09-0124
17. Hukkinen M, Korhonen T, Broms U, et al. Long-Term Smoking Behavior Patterns Predicting Self-Reported Chronic Bronchitis. J COPD. 2009;6:242-9. DOI:10.1080/15412550903051781
18. Faessel H, Ravva P, Williams K. Pharmacokinetics, safety, and tolerability of varenicline in healthy adolescent smokers: a multicenter, randomized, double-blind, placebocontrolled, parallel-group study. Clin Ther. 2009;31:177-89. DOI:10.1016/j.clinthera.2009.01.003
19. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained- release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999;340:685-91. DOI:10.1056/NEJM199903043400903
20. Willemse BWM, Postma DS, Timens W, ten Hacken NHT. The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation. Eur Respir J. 2004;23:464-76. DOI:10.1183/09031936.04.00012704
21. Poole P, Black PN. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2010;2: CD001287. DOI:10.1002/14651858.CD001287.pub3
22. Poole P, Sathananthan K, Fortescue R. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2019;5(5):CD001287. DOI:10.1002/14651858.CD001287.pub6
23. Kardos P, Berck H, Fuchs KH, et al. Guidelines of the German respiratory society for diagnosis and treatment of adults suffering from acute or chronic cough. Pneumologie. 2010;64:701-11. DOI:10.1055/s-0030-1255526
24. Kardos P, Dinh QT, Fuchs KH, et al. Guidelines of the German Respiratory Society for Diagnosis and Treatment of Adults Suffering from Acute, Subacute and Chronic. Cough Pneumologie. 2019;73:143-10. DOI:10.1055/a-0808-7409
25. Ghafouri R, Patil K, Kass I. Sputum changes associated with the use of ipratropium bromide. Chest. 1984;86:387-93. DOI:10.1378/chest.86.3.387
26. Melloni B, Germouty J. The influence of a new beta agonist formoterol on mucociliary function. Rev Mal Respir. 1992;9:503-7.
27. Ram F, Jones P, Castro A, et al. Oral theophylline for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2002;4. DOI:10.1002/14651858.CD003902
28. Lai K, Shen H, Zhou X, et al. Clinical Practice Guidelines for Diagnosis and Management of Cough-Chinese Thoracic Society (CTS) Asthma Consortium. J Thorac Dis. 2018;10:6314-51. DOI:10.21037/jtd.2018.09.153
29. Staykova T, Black P, Chacko E, et al. Prophylactic antibiotic therapy for bronchitis. Cochrane Database Syst Rev. (database online). 2004;4. 
30. Dimopoulos G, Siempos II, Korbila IP, et al. Comparison of first line with secondline antibiotics for acute exacerba tions of chronic bronchitis: a meta-analysis of randomized controlled trials. Chest. 2007;132:447-55. 
31. Siempos II, Dimopoulos G, Korbila IP, et al. Macro-lides, quinolones and amoxicillin/clavulanate for chronic bronchitis: a meta-analysis. Eur Respir J. 2007;29(6):1127-37. DOI:10.1183/09031936.00147806
32. Falagas M, Avgeri S, Matthaiou D, Dimopoulos G. Short-versus long-duration antimicrobial treatment for exacerbations of chronic bronchitis: a meta-analysis. J Antimicrob Chemother. 2008;62(3):442-50. 
33. Adler JL, Jannetti W, Schneider D, et al. Phase III, randomized, double-blind study of clarithromycin extended-release and immediate-release formulations in the treatment of patients with acute exacerbation of chronic bronchitis. Clin Ther. 2000;22(12):1410-20. DOI:10.1016/s0149-2918(00)83040-4
34. Mahashur A. Management of lower respiratory tract infection in outpa-tient settings: Focus on clarithromycin. Lung India. 2018;35(2):143-9. DOI:0.4103/lungindia.lungindia_262_17
35. Miravitlles M, Espinosa C, Fernandez-Laso E, et al. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest. 1999;116(1):40-6. 
36. Синопальников А.И., Зайцев А.А. Антибактериальная терапия при обострении хронической обструктивной болезни легких: фокус на длительность «безынфекционного» периода. Consilium Medicum. 2012;14(3):74-8 [Sinopalnikov AI, Zaitsev AA. Antibakterialnaia terapia pri obostrenii khronicheskoi obstruktivnoi bolezni legkikh: fokus na dlitelnost “bezynfektsionnogo” perioda. Consilium Medicum. 2012;14(3):74-8 (in Russian)].
37. Lorenz J, Steinfeld P, Drath L, et al. Efficacy and Tolerability of 5- vs 10-Day Cefixime Therapy in Acute Exacerbations of Chronic Bronchitis. Clin Drug Investig. 1998;15(1):13-20.
38. Синопальников А.И., Зайцев А.А. Комплаентность пациентов с инфекциями дыхательных путей. Клиническая микробиология и антимикробная химиотерапия. 2008;1:50-9 [Sinopalnikov AI, Zaitsev AA. Patient compliance with antimicrobial therapy of lower respiratory tract infections. Klinicheskaia mikrobiologiia i antimikrobnaya khimioterapiia. 2008;1:50-9 (in Russian)]. 
39. Chodosh S, DeAbate C, Haverstock D, et al. Short-course moxifloxa-cin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. Respir Med. 2000;94:18-27. DOI:10.1053/rmed.1999.0708
40. Masterton R, Burley C. Randomized, double-blind study comparing 5- and 7-day regimens of oral levofloxacin in patients with acute exacerbation of chronic bronchitis. Int J Antimicrob Agents. 2001;18:503-12.
41. Higgings BG, Powell RM, Cooper S, Tattersfield AE. Effect of salbutamol and ipratropium bromide on airway calibre and bronchial reactivity in asthma and chronic bronchitis. Eur Respir J. 1991;4:415-20.
42. Walters JAE, Tan DJ, White CJ, et al. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;9:112-34. DOI:10.1002/14651858.CD001288.pub4
43. Gunen H, Hacievliyagil SS, Yetkin O, et al. The role of nebulised budesonide in the treatment of exacerbations of COPD. Eur Respir J. 2007;29(4):660-7. DOI:10.1183/09031936.00073506
44. Avdeev SN, Vizel AA, Abrosimo VN, et al. Management of Cough in Patients with Chronic Obstructive Pulmonary Disease: Results of the Multicenter Randomized Placebo-Controlled Clinical Trial. Int J Chronic Obstruct Pulm Dis. 2021;16:1243-53. DOI:10.2147/COPD.S292109
45. Nici L, Donner C, Wouters E, et al. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med. 2006;173:1390-413. DOI:10.1164/rccm.200508-1211ST
46. Ries AL, Bauldoff GS, Carlin BW, et al. Pulmonary Rehabilitation: Joint ACCP/AACVPR Evidence-Based Clinical Practice Guidelines. Chest. 2007;131:4S-42S. DOI:10.1378/chest.06-2418
47. Баранов А.А., Намазова-Баранова Л.С., Брико Н.И., и др. Вакцинопрофилактика пневмококковой инфекции у детей и взрослых. Методические рекомендации. М. 2023 [Baranov AA, Namazova-Baranova LS, Briko NI, et al. Vaktsinoprofilaktika pnevmokokkovoi infektsii u detei i vzroslykh. Metodicheskie rekomendatsii. Moscow. 2023 (in Russian)].
48. Fraser A, Poole P. Immunostimulants versus placebo for preventing exacerbations in adults with chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2022;11(11):CD013343. DOI:10.1002/14651858.CD013343.pub2
49. Gareri P, Trevisan C, Abbatecola AM, et al. Efficacy Of Om-85 In Recurrent Respiratory Tract Infections. Rev Recent Clin Trials. 2023;18(3):223-7. DOI:10.2174/1574887118666230518112806

________________________________________________

1. Miravitlles M, Soriano JB, García-Río F, et al. Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities. Thorax. 2009;64(10):863-8. DOI:10.1136/thx.2009.115725
2. Martinez C, Chen Y, Kazerooni E, et al. Non-obstructive chronic bronchitis in the COPDGene cohort. Am J Respir Crit Care Med. 2012;185:A6622. DOI:10.1164/ajrccm-conference.2012.185.1_MeetingAbstracts.A6622
3. Kosarev VV, Babanov SA. Social aspects of chronic bronchitis according to data of epidemiologic study. Ekologiia cheloveka. 2005;12:46-9 [(in Russian). 
4. Smith JA, Woodcock A. Chronic cough. N Engl J Med. 2016;375:1544-51. DOI:10.1056/NEJMcp1414215
5. Leshchenko IV, Demko IV, Zaytsev AA, et al. Khronicheskii bronkhit. Pod red. IV Leshchenko. Moscow: GEOTAR-Media, 2021 (in Russian). 
6. Zaitsev AA, Okovityi SV, Kriukov EV. Kashel. Prakticheskoie posobie dlia vrachei. Moscow, 2015 (in Russian).
7. Terasaki G, Paauw DS. Evaluation and treatment of chronic cough. Med Clin N Am. 2014;98:91-403. DOI:10.1016/j.mcna.2014.01.002
8. Achilleos A. Evidence-based evaluation and management of chronic cough. Med Clin N Am. 2016;100:1033-45. DOI:10.1016/j.mcna.2016.04.008
9. Dotan Y, So JY, Kim V. Chronic Bronchitis: Where Are We Now? Chronic Obstr Pulm Dis. 2019;6(2):178-92. DOI:10.15326/jcopdf.6.2.2018.0151
10. Lai K, Shen H, Zhou X, et al. Clinical practice guidelines for diagnosis and management of cough: Chinese Thoracic Society (CTS) Asthma Consortium. J Thorac Dis. 2018;10:6314-51. DOI:10.21037/jtd.2018.09.153
11. Irwin RS. Chronic Cough Due to Gastroesophageal Reflux Disease ACCP evidence-based clinical practice guidelines. Chest. 2006;129(Suppl. 1):59S-62S. DOI:10.1378/chest.129.1_suppl.80S
12. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106(2):196-204. DOI:10.7326/0003-4819-106-2-196
13. Woodhead M, Blasi F, Ewig S, et al. New guidelines for the management of adult lover respiratory tract infections. Clin Microbiol Infect. 2011;17(6):1-59. DOI:10.1111/j.1469-0691.2011.03602.x
14. Irwin RS, Baumann MH, Bolser DC, et al. Diagnosis and management of cough executive summary: ACCP evidence-based clinical practice guidelines. Chest. 2006;29(1 Suppl.):1S-23S. DOI:10.1378/chest.129.1_suppl.1S
15. Morice AH, Millqvist E, Bieksiene K, et al. ERS guidelines on the diagnosis and treatment of chronic cough in adults and children. Eur Respir J. 2020;55:1901136 DOI:10.1183/13993003.01136-2019
16. Chandler MA, Rennard SI. Smoking cessation. Chest. 2010;137:428-35. DOI:10.1378/chest.09-0124
17. Hukkinen M, Korhonen T, Broms U, et al. Long-Term Smoking Behavior Patterns Predicting Self-Reported Chronic Bronchitis. J COPD. 2009;6:242-9. DOI:10.1080/15412550903051781
18. Faessel H, Ravva P, Williams K. Pharmacokinetics, safety, and tolerability of varenicline in healthy adolescent smokers: a multicenter, randomized, double-blind, placebocontrolled, parallel-group study. Clin Ther. 2009;31:177-89. DOI:10.1016/j.clinthera.2009.01.003
19. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained- release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999;340:685-91. DOI:10.1056/NEJM199903043400903
20. Willemse BWM, Postma DS, Timens W, ten Hacken NHT. The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation. Eur Respir J. 2004;23:464-76. DOI:10.1183/09031936.04.00012704
21. Poole P, Black PN. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2010;2: CD001287. DOI:10.1002/14651858.CD001287.pub3
22. Poole P, Sathananthan K, Fortescue R. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2019;5(5):CD001287. DOI:10.1002/14651858.CD001287.pub6
23. Kardos P, Berck H, Fuchs KH, et al. Guidelines of the German respiratory society for diagnosis and treatment of adults suffering from acute or chronic cough. Pneumologie. 2010;64:701-11. DOI:10.1055/s-0030-1255526
24. Kardos P, Dinh QT, Fuchs KH, et al. Guidelines of the German Respiratory Society for Diagnosis and Treatment of Adults Suffering from Acute, Subacute and Chronic. Cough Pneumologie. 2019;73:143-10. DOI:10.1055/a-0808-7409
25. Ghafouri R, Patil K, Kass I. Sputum changes associated with the use of ipratropium bromide. Chest. 1984;86:387-93. DOI:10.1378/chest.86.3.387
26. Melloni B, Germouty J. The influence of a new beta agonist formoterol on mucociliary function. Rev Mal Respir. 1992;9:503-7.
27. Ram F, Jones P, Castro A, et al. Oral theophylline for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2002;4. DOI:10.1002/14651858.CD003902
28. Lai K, Shen H, Zhou X, et al. Clinical Practice Guidelines for Diagnosis and Management of Cough-Chinese Thoracic Society (CTS) Asthma Consortium. J Thorac Dis. 2018;10:6314-51. DOI:10.21037/jtd.2018.09.153
29. Staykova T, Black P, Chacko E, et al. Prophylactic antibiotic therapy for bronchitis. Cochrane Database Syst Rev. (database online). 2004;4. 
30. Dimopoulos G, Siempos II, Korbila IP, et al. Comparison of first line with secondline antibiotics for acute exacerba tions of chronic bronchitis: a meta-analysis of randomized controlled trials. Chest. 2007;132:447-55. 
31. Siempos II, Dimopoulos G, Korbila IP, et al. Macro-lides, quinolones and amoxicillin/clavulanate for chronic bronchitis: a meta-analysis. Eur Respir J. 2007;29(6):1127-37. DOI:10.1183/09031936.00147806
32. Falagas M, Avgeri S, Matthaiou D, Dimopoulos G. Short-versus long-duration antimicrobial treatment for exacerbations of chronic bronchitis: a meta-analysis. J Antimicrob Chemother. 2008;62(3):442-50. 
33. Adler JL, Jannetti W, Schneider D, et al. Phase III, randomized, double-blind study of clarithromycin extended-release and immediate-release formulations in the treatment of patients with acute exacerbation of chronic bronchitis. Clin Ther. 2000;22(12):1410-20. DOI:10.1016/s0149-2918(00)83040-4
34. Mahashur A. Management of lower respiratory tract infection in outpa-tient settings: Focus on clarithromycin. Lung India. 2018;35(2):143-9. DOI:0.4103/lungindia.lungindia_262_17
35. Miravitlles M, Espinosa C, Fernandez-Laso E, et al. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest. 1999;116(1):40-6. 
36. Sinopalnikov AI, Zaitsev AA. Antibakterialnaia terapia pri obostrenii khronicheskoi obstruktivnoi bolezni legkikh: fokus na dlitelnost “bezynfektsionnogo” perioda. Consilium Medicum. 2012;14(3):74-8 (in Russian).
37. Lorenz J, Steinfeld P, Drath L, et al. Efficacy and Tolerability of 5- vs 10-Day Cefixime Therapy in Acute Exacerbations of Chronic Bronchitis. Clin Drug Investig. 1998;15(1):13-20.
38. Sinopalnikov AI, Zaitsev AA. Patient compliance with antimicrobial therapy of lower respiratory tract infections. Klinicheskaia mikrobiologiia i antimikrobnaya khimioterapiia. 2008;1:50-9 (in Russian). 
39. Chodosh S, DeAbate C, Haverstock D, et al. Short-course moxifloxa-cin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. Respir Med. 2000;94:18-27. DOI:10.1053/rmed.1999.0708
40. Masterton R, Burley C. Randomized, double-blind study comparing 5- and 7-day regimens of oral levofloxacin in patients with acute exacerbation of chronic bronchitis. Int J Antimicrob Agents. 2001;18:503-12.
41. Higgings BG, Powell RM, Cooper S, Tattersfield AE. Effect of salbutamol and ipratropium bromide on airway calibre and bronchial reactivity in asthma and chronic bronchitis. Eur Respir J. 1991;4:415-20.
42. Walters JAE, Tan DJ, White CJ, et al. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;9:112-34. DOI:10.1002/14651858.CD001288.pub4
43. Gunen H, Hacievliyagil SS, Yetkin O, et al. The role of nebulised budesonide in the treatment of exacerbations of COPD. Eur Respir J. 2007;29(4):660-7. DOI:10.1183/09031936.00073506
44. Avdeev SN, Vizel AA, Abrosimo VN, et al. Management of Cough in Patients with Chronic Obstructive Pulmonary Disease: Results of the Multicenter Randomized Placebo-Controlled Clinical Trial. Int J Chronic Obstruct Pulm Dis. 2021;16:1243-53. DOI:10.2147/COPD.S292109
45. Nici L, Donner C, Wouters E, et al. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med. 2006;173:1390-413. DOI:10.1164/rccm.200508-1211ST
46. Ries AL, Bauldoff GS, Carlin BW, et al. Pulmonary Rehabilitation: Joint ACCP/AACVPR Evidence-Based Clinical Practice Guidelines. Chest. 2007;131:4S-42S. DOI:10.1378/chest.06-2418
47. Baranov AA, Namazova-Baranova LS, Briko NI, et al. Vaktsinoprofilaktika pnevmokokkovoi infektsii u detei i vzroslykh. Metodicheskie rekomendatsii. Moscow. 2023 (in Russian).
48. Fraser A, Poole P. Immunostimulants versus placebo for preventing exacerbations in adults with chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2022;11(11):CD013343. DOI:10.1002/14651858.CD013343.pub2
49. Gareri P, Trevisan C, Abbatecola AM, et al. Efficacy Of Om-85 In Recurrent Respiratory Tract Infections. Rev Recent Clin Trials. 2023;18(3):223-7. DOI:10.2174/1574887118666230518112806

И.В. Лещенко*^1,2, С.Н. Авдеев^3,4, А.А. Зайцев^5,6, С.И. Овчаренко³, от имени рабочей группы по разработке и пересмотру новых клинических рекомендаций по хроническому бронхиту

¹ФГБОУ ВО «Уральский государственный медицинский университет» Минздрава России, Екатеринбург, Россия;
²Уральский научно-исследовательский институт фтизиопульмонологии – филиал ФГБУ «Национальный медицинский исследовательский центр фтизиопульмонологии и инфекционных заболеваний» Минздрава России, Екатеринбург, Россия;
³ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия;
⁴ФГБУ «Научно-исследовательский институт пульмонологии» ФМБА России, Москва, Россия;
⁵ФГБОУ ВО «Российский биотехнологический университет (РОСБИОТЕХ)», Москва, Россия;
⁶ФГБОУ ВО «Российский университет медицины» Минздрава России, Москва, Россия
*leshchenkoiv@yandex.ru

________________________________________________

Igor V. Leshchenko*^1,2, Sergey N. Avdeev^3,4, Andrey A. Zaytsev^5,6, Svetlana I. Ovcharenko³, on behalf of the working group for the development and revision of clinical guidelines for chronic bronchitis

¹Ural State Medical University, Yekaterinburg, Russia;
²Ural Research Institute of Phthisiopulmonology – branch of the National Medical Research Center for Phthisiopulmonology and Infectious Diseases, Yekaterinburg, Russia;
³Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia;
⁴Research Institute of Pulmonology, Moscow, Russia;
⁵BIOTECH University, Moscow, Russia;
⁶Russian University of Medicine, Moscow, Russia
*leshchenkoiv@yandex.ru